Alcohol Use Disorder (AUD) Clinical Trial Monitor

The alcohol use disorder clinical trial landscape in 2026

Alcohol use disorder is one of the most prevalent and undertreated conditions in psychiatry. Despite three FDA-approved medications (naltrexone, acamprosate, disulfiram) and one injectable (naltrexone ER), treatment rates remain low and outcomes are often poor. The pipeline reflects growing interest in novel mechanisms, including GLP-1 receptor agonists and psychedelic-assisted therapy.

The most commercially significant development in 2026 is the GLP-1 receptor agonist signal in addiction. Semaglutide and liraglutide have shown early evidence of reducing alcohol consumption in observational studies and small trials, generating significant industry interest in repositioning or developing GLP-1 analogs for AUD. Multiple industry-funded trials are underway, and this mechanism has the potential to transform the addiction pharmacotherapy market.

• GLP-1 receptor agonists: Semaglutide, liraglutide, and novel analogs being tested for reduction in alcohol craving and consumption
• Naltrexone variants: Depot formulations, combination approaches, novel opioid receptor modulators
• GABA modulation: Neurosteroids, GABA-A modulators targeting the anxiety and withdrawal component of AUD
• Nalmefene: Opioid receptor modulator with EU approval, Phase 3 trials in US populations
• Psychedelic-assisted therapy: Psilocybin-assisted therapy for AUD — several Phase 2 trials underway at academic centers
• Digital therapeutics: Software-based CBT and contingency management being tested as standalone or adjunct interventions

Who uses alcohol use disorder trial monitoring

CNS pharma BD and addiction medicine companies

The GLP-1 opportunity in addiction has attracted multiple pharmaceutical companies to the AUD space. Companies developing GLP-1 receptor agonists, as well as those with existing CNS/addiction franchises, need to track Phase 2 and Phase 3 readouts to understand the competitive positioning of their programs.

Addiction medicine researchers and NIDA/NIAAA grantees

Academic researchers funded by NIAAA and NIDA monitor the competitive landscape to avoid duplication and identify collaboration opportunities. The AUD trial space is heavily academic, with NIAAA directly sponsoring many trials.

Behavioral health investors

The potential for GLP-1 agonists in addiction has drawn investor attention to the AUD pharmacotherapy space. Monitoring Phase 2 readouts and new trial registrations is essential for investors tracking addiction biotech valuations.

Current AUD trial activity (as of March 2026)

Phase	Recruiting Trials	Key Sponsors
Phase 3	3	Industry sponsors, NIAAA
Phase 2	13	Yale, NIAAA, NIDA, Medical University of South Carolina
Phase 1 / Phase 1–2	6	Academic medical centers, biotechs
Total recruiting	59	Primarily academic and NIH-funded

Frequently asked questions

How current is the AUD trial data?

Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.

Can I monitor both pharmacological and behavioral AUD trials?

Yes. Use keywords like "naltrexone", "acamprosate", "GLP-1", or "behavioral" to focus on specific intervention types within the AUD trial space.

Does DataLookout cover co-occurring conditions in AUD trials?

Yes — many AUD trials include co-occurring depression, anxiety, or other substance use disorders. You can add related keywords to your watchlist to capture cross-indication programs.

How is DataLookout different from ClinicalTrials.gov alerts?

ClinicalTrials.gov offers basic notifications without phase filtering or organized daily digests. DataLookout delivers a structured daily summary — designed for professional pipeline monitoring.